experimental placebo

Phase 3

BBrainfarma Industria Química e Farmacêutica S/A

experimental placebo is one of 33 therapeutic programs targeting Diabetic Neuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Diabetic NeuropathyRecruiting

Diabetic NeuropathyPhase 3

Recruiting

Competition

Competitive Landscape

34 competitors in Diabetic Neuropathy

#DrugCompanyPhaseTrials

Cymbalta

Jazz Pharmaceuticals

Approved

2 2

Aricept

Eisai

Approved

1 3

Tegretol

Novartis

Approved

1 4

Farxiga

AstraZeneca

Approved

—5

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 6

Neurontin

VViatris Specialty LLC

Approved

4 7

Elavil

Avandia

Calciferol

Epidiolex

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Diabetic Neuropathy

NCT07712913

Clinical

Trials by Indication[1]

Diabetic Neuropathy1 trial

A Phase III, Multicenter, Randomized, Double-blind, Double-dummy, Controlled, Parallel-group, Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of Extended-release Pregabalin Tablets Compared With Immediate-release Pregabalin Tablets, in the Relief of Neuropathic Pain in Participants With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia.

Recruiting·BBrainfarma Industria Química e Farmacêutica S/A·Phase 3·NCT07712913·348 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for experimental placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for experimental placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Brainfarma Industria Química e Farmacêutica S/A company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: BBrainfarma Industria Química e Farmacêutica S/A

experimental placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Diabetic Neuropathy1 trial

References

Drug Info

Quick Facts

Related News